Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 5/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386147 | 0.85 | RBP4 (0.42) | RBP4NAMPTGAAHDAC1HDAC6 | |
| SCHEMBL5465401 | 0.84 | KDM4E (0.47) | RBP4NAMPTCDK5CDK5R1GAA | |
| SCHEMBL22482203 | 0.84 | CDK5 (0.44) | RBP4NAMPTCDK5CDK5R1GAA | |
| SCHEMBL22482006 | 0.84 | RBP4 (0.41) | RBP4NAMPTCDK5CDK5R1GAA | |
| SCHEMBL17870541 | 0.81 | RBP4 (0.39) | RBP4ESR2ADORA1NR1H2CREBBP | |
| SCHEMBL22029668 | 0.81 | NAMPT (0.36) | RBP4NAMPTCDK5CDK5R1GAA | |
| SCHEMBL4792110 | 0.81 | ADORA1 (0.46) | RBP4ESR2ADORA1NR1H2CREBBP | |
| SCHEMBL14520683 | 0.81 | ESR2 (0.41) | RBP4ESR2ADORA1NR1H2CREBBP | |
| SCHEMBL4795587 | 0.81 | NPC1 (0.48) | RBP4CDK5CDK5R1GAAL3MBTL1 | |
| SCHEMBL17870535 | 0.81 | RBP4 (0.39) | RBP4ESR2ADORA1NR1H2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9890161-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9527845-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885NAMPT 329/4885CDK5 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.